Overview

* Aytu BioPharma ( AYTU ) fiscal 2025 revenue up 2% to $66.4 mln, misses Q4 estimates

* Net loss narrows to $13.6 mln from $15.8 mln in fiscal 2024

* EXXUA launch in fourth calendar quarter of 2025 expected to drive future growth

Outlook

* Aytu to launch EXXUA in fourth calendar quarter of 2025

* Company expects EXXUA to enter $22 bln US MDD market

* Aytu anticipates EXXUA to drive significant growth in fiscal 2026

Result Drivers

* ADHD REVENUE DECLINE - ADHD Portfolio revenue decreased slightly due to fewer prescriptions, offset by improved brand economics through Aytu RxConnect

* PEDIATRIC GROWTH - Pediatric Portfolio revenue grew, driven by a return-to-growth plan that increased unit sales by 49%

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Miss $15.14 $17.90

Revenue mln mln (3

Analysts

)

Q4 Net -$19.82

Income mln

Q4 Miss $2 mln $2.76

Adjusted mln (3

EBITDA Analysts

)

Q4 Gross $10.25

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Aytu Biopharma Inc ( AYTU ) is $9.00, about 72.3% above its September 22 closing price of $2.49

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)